On Nov. 19, 2020, Novartis announced that it had entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.

Remestemcel-L was being studied in COVID-19-related ARDS in an ongoing 300-patient Phase III study.